secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2021-12-27T23:59:59+00:00
Accession:  0001104659-21-153559
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte CSO Jeffrey Lawson to depart effective Dec 31, 2022; no disagreement cited
--------------------------------------------------------------------------------

- Dr. Jeffrey H. Lawson, Chief Surgical Officer, leaves Humacyte effective Dec 31, 2022, and resigns from board.
- Departure is mutual, not due to any disagreement with company operations, policies, or practices.
- Severance benefits per existing employment agreement; vested stock option exercise period extended to Nov 26, 2022.
- Separation agreement includes customary release of claims and supersedes other severance arrangements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465921153559/0001104659-21-153559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465921153559/tm2136325d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-153559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer